Germany’s draft GKV Contribution Rate Stabilisation Act signals a clearly tighter environment for pharmaceutical pricing and market access, even though it also removes some of the most rigid features introduced in 2022.
The Federal Ministry of Health’s ministerial draft, dated 16 April 2026, is designed to stabilise statutory health insurance contribution rates from 2027 onwards in response to a nearly €10 billion SHI deficit in 2024 and a
projected financing gap that could reach around €40 billion by 2030 without structural reform.
Dynamic manufacturer rebate: higher uncertainty for net prices
For pharmaceutical companies, the most consequential provision is the introduction of an additional dynamic manufacturer rebate. In legal terms, this is not a new launch-price rule but an additional rebate on the manufacturer price for in-scope medicines dispensed at SHI expense.
Continue reading the full analysis
Download Remap’s full expert analysis to explore:
- The implications of the new dynamic manufacturer rebate
- Expanded rebate-contract competition in patent-protected markets
- Strengthened price-volume controls and AMNOG negotiation changes
- Strategic considerations for pricing, evidence generation, and market access teams